Fatigue News and Research

RSS

$3 billion announced for global malaria action plan to eradicate malaria by 2015

Government leaders, philanthropists, international organizations, not-for-profit groups and corporations on Thursday announced a combined $3 billion in contributions to implement the Global Malaria Action Plan -- aimed at eradicating malaria worldwide by 2015 -- during the United Nations General Assembly High-Level Meeting on the U.N. Millennium Development Goals in New York, the Wall Street Journal reports.

29 Sep 2008

Researchers investigate impact of stress on police officers' physical and mental health

Policing is dangerous work, and the danger lurks not on the streets alone. The pressures of law enforcement put officers at risk for high blood pressure, insomnia, increased levels of destructive stress hormones, heart problems, post-traumatic stress disorder (PTSD) and suicide, University at Buffalo researchers have found through a decade of studies of police officers.

25 Sep 2008

Research evaluates acupressure for chemo induced nausea

New research commissioned by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme is evaluating acupressure wristbands for the management of chemotherapy-induced acute and delayed nausea.

23 Sep 2008

FDA grants approval to Talecris Biotherapeutics for Gamunex for neurological disorder CIDP

Talecris Biotherapeutics, Inc. announced today the U.S. Food and Drug Administration (FDA) has granted approval for Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a debilitating neurological disorder that results in muscle weakness and fatigue, which can lead to severe impairment of motor skills.

15 Sep 2008

Keppra XR approved in the U.S. for partial onset seizures

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Keppra XR (levetiracetam extended-release tablets) for use as an add-on to other antiepileptic treatments for people with partial onset seizures who are 16 years of age and older. Keppra XR is expected to be available in U.S. pharmacies at the end of September 2008.

15 Sep 2008

Men's health campaign launched to address often overlooked physical, emotional and sexual issues affecting men with diabetes

In addition to dealing with the day-to-day aspects of diabetes management that involve blood glucose, nutrition and lifestyle management, men in the United States with diabetes are also grappling with other physical, emotional and sexual health issues according to survey findings released today by the American Diabetes Association.

9 Sep 2008

Myalgic encephalomyelitis sufferers rely on aternative medicines

More than a third of patients with long-term fatigue conditions like Myalgic Encephalomyelitis (ME) believe complementary and alternative medicines (CAMs) are more effective than traditional medicine in treating their illness, research launched at the British Pharmaceutical Conference (BPC) in Manchester reveals.

7 Sep 2008

NIH tackles urologic chronic pelvic pain disorders

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH), announces awards to eight academic research centers to conduct collaborative studies of urologic chronic pelvic pain disorders by looking for clues outside the bladder and prostate. The total research investment for the five-year project is estimated to be up to $37.5 million.

7 Sep 2008

FDA forces manufacturers of TNF-blockers to highlight risk of fungal infections

The U.S. Food and Drug Administration today announced that the manufacturers of Humira, Cimzia, Enbrel, and Remicade must strengthen the existing warnings, in the Warnings and Precaution sections of the drugs' prescribing information and Medication Guides, on the risk of developing opportunistic fungal infections. Some patients with invasive fungal infections have died.

5 Sep 2008

FDA approves DNA test to measure hepatitis B viral load

The U.S. Food and Drug Administration today approved the first nucleic acid test for hepatitis B virus (HBV) that measures the amount of viral DNA (viral load) in a patient's blood. Assessing a patient's viral load provides health care professionals with a highly sensitive method for gauging the progress of antiviral therapy in patients with chronic HBV infections.

5 Sep 2008

Stress and depression compromising the safety of Australia's truck drivers

A new report raises concerns about the mental well being of many of Australia's truck drivers.

4 Sep 2008

Depression drug Cymbalta eases chronic back pain

A drug used to treat depression has been found to also be effective in reducing chronic low back pain.

28 Aug 2008

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008

Hunt for baby denied HBV shot

Authorities in New South Wales, Australia, continue to search for a couple who have refused to have their newborn baby immunised against hepatitis B.

25 Aug 2008

Cymbalta approved in Europe for generalised anxiety disorder

Eli Lilly and Co and Boehringer Ingelheim have announced that the European Commission has approved the use of Cymbalta (duloxetine) for the treatment of Generalised Anxiety Disorder (GAD).

24 Aug 2008

One night without sleep increases chemical dopamine in the human brain

Because drugs that increase dopamine, like amphetamines, promote wakefulness, the findings offer a potential mechanism explaining how the brain helps people stay awake despite the urge to sleep. However, the study also shows that the increase in dopamine cannot compensate for the cognitive deficits caused by sleep deprivation.

19 Aug 2008

Alternative vaccine strategy shows promise in prostate cancer patients

New research indicates that giving patients a continuous low dose of an immune system booster, a method known as metronomic dosing, as part of a therapeutic prostate cancer vaccine strategy is safe and produces similar immune responses and fewer side effects than the more common dosing method, which is not well tolerated by many patients. This study, led by researchers at that National Cancer Institute (NCI), part of the National Institutes of Health, was published in the Aug. 15, 2008, issue of Clinical Cancer Research.

17 Aug 2008

Study finds caregivers of spouses with dementia report sadness and loneliness

Spouses of husbands and wives with dementia pay an emotional toll as they care for their ailing spouse. This has prompted a call for new interventions and strategies to assist caregivers in coping with the demands of this difficult time, according to a study from Case Western Reserve University's Mandel School of Applied Social Sciences.

12 Aug 2008

Precisely targeted radiation therapy can control limited cancer spread

Precisely targeted radiation therapy can eradicate all evidence of disease in selected patients with cancer that has spread to only a few sites, suggests the first published report from an ongoing clinical trial.

12 Aug 2008

Too many women ignorant of symptoms of ovarian cancer

A new survey had revealed that though ovarian cancer remains one of biggest gynaecological cancer killers, many women are unsure or unaware of the symptoms of the disease.

10 Aug 2008